



UV light assisted antibiotics for eradication of in vitro biofilms

Argyraki, Aikaterini; Markvart, Merete; Stavnsbjerg, Camilla; Kragh, Kasper Nørskov; Ou, Yiyu; Bjørndal, Lars; Bjarnsholt, Thomas; Petersen, Paul Michael

Published in:
Scientific Reports

Link to article, DOI:
[10.1038/s41598-018-34340-8](https://doi.org/10.1038/s41598-018-34340-8)

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)


Citation (APA):
Argyraki, A., Markvart, M., Stavnsbjerg, C., Kragh, K. N., Ou, Y., Bjørndal, L., ... Petersen, P. M. (2018). UV light assisted antibiotics for eradication of in vitro biofilms. *Scientific Reports*, 8(1), [16360]. DOI: 10.1038/s41598-018-34340-8

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Københavns Universitet

UV light assisted antibiotics for eradication of in vitro biofilms

Argyraki, Aikaterini; Markvart, Merete; Stavnsbjerg, Camilla; Kragh, Kasper Nørskov; Ou, Yiyu; Bjørndal, Lars; Bjarnsholt, Thomas; Petersen, Paul Michael

Published in:
Scientific Reports

DOI:
[10.1038/s41598-018-34340-8](https://doi.org/10.1038/s41598-018-34340-8)

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Argyraki, A., Markvart, M., Stavnsbjerg, C., Kragh, K. N., Ou, Y., Bjørndal, L., ... Petersen, P. M. (2018). UV light assisted antibiotics for eradication of in vitro biofilms. *Scientific Reports*, 8, 1-9. [16360].
<https://doi.org/10.1038/s41598-018-34340-8>

SCIENTIFIC REPORTS



OPEN

UV light assisted antibiotics for eradication of *in vitro* biofilms

Aikaterini Argyraki¹, Merete Markvart², Camilla Stavnsbjerg^{3,4}, Kasper Nørskov Kragh³, Yiyu Ou¹, Lars Bjørndal², Thomas Bjarnsholt^{3,4} & Paul Michael Petersen¹

Received: 14 February 2018

Accepted: 9 October 2018

Published online: 05 November 2018

The overuse of antibiotics is accelerating the bacterial resistance, and therefore there is a need to reduce the amount of antibiotics used for treatment. Here, we demonstrate *in vitro* that specific wavelengths in a narrow range around 296 nm are able to eradicate bacteria in the biofilm state (grown for 24 hours) more effectively, than antibiotics and the combination of irradiation and antibiotics is even better, introducing a novel concept *light assisted antibiotics*. The investigated wavelength range was 249 nm to 338 nm with an approximate step of 5 nm. The novel concept that consists of a UV irradiation treatment followed by a tobramycin treatment can significantly reduce the amount of antibiotics needed for eradicating mature bacterial biofilms. The efficiency of the proposed light assisted antibiotics method was compared to combinatory antibiotic treatment and highly concentrated antibiotic monotherapy. The eradication efficacies, on mature biofilms, achieved by light assisted antibiotic and by the antibiotic monotherapy at approximately 10-fold higher concentration, were equivalent. The present achievement could motivate the development of light assisted antibiotic treatments for treating infections.

There is a worldwide increasing awareness and concern about the antibiotic resistance, which in the future could prevent effective treatment of a large number of infectious diseases¹. The emergency of antibiotic resistance has evoked a “turn” towards antibiotics control/reduction programs². Moreover, biofilm infections are highly persistent to the immune response and known for their tolerance to antibiotic treatments³. Alternative approaches, different than conventional antibiotic treatments, are gaining increasing interest and light based treatments⁴ are unconventional strategies for biofilm eradication. Bak *et al.* has reported disinfection potential of catheter lumens by UVC LEDs⁵. Recently, we have observed that UVB irradiation is more efficient than UVC, in eradicating biofilms plated on cellulose nitrate membrane filters⁶. However, the ultraviolet (UV) wavelength dependent eradication efficiency for *Pseudomonas aeruginosa* biofilms has not been reported. Apart from UV light, also exposure to blue light has been proven to have antimicrobial effect, without the requirement of exogenous photosensitizers present⁷.

UV light emitting diodes (LEDs) are progressing as light source options in biomedical applications mainly due to their flexibility in spectral design and ease in operation. AlGaN LEDs are continuously progressing as UV light sources. A wavelength as short as 210 nm has been achieved with pure AlN LEDs⁸. External quantum efficiency (EQE) of UV LEDs is continuously improving as both internal quantum efficiency (IQE) and light extraction efficiency (LEE) are boosted by various techniques like: migration-enhanced metalorganic chemical vapor deposition^{9,10}, ammonia pulsed-flow method^{11,12} and nanowires¹³, or surface plasmons¹⁴ and aluminum reflective electrodes¹⁵, respectively. EQE above 10% has been reported when approaches for improving IQE and LEE are applied in combination¹⁶.

Combinatory therapies seem to be the solution for combating tolerant biofilms present in chronic infections^{17,18}. Particularly, if the combinatory treatments enact complementary mode of actions then synergy can be expected, and therefore, better eradication efficiency^{19–21}.

Biofilms are complex formations created by bacteria to improve their chances of survival. More specifically, biofilms can be 10 to 1000 times more tolerant than the planktonic phenotype²². The organization and

¹Department of Photonics Engineering, Technical University of Denmark, Frederiksborgvej 399, DK-4000, Roskilde, Denmark. ²Cariology and Endodontics, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Nørre Allé 20, DK-2200, Copenhagen N, Denmark. ³Department of Immunology and Microbiology, Costerton Biofilm Center, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark. ⁴Department of Clinical Microbiology, Rigshospitalet, Juliane Maries vej 22, 2100, Copenhagen Ø, Denmark. Correspondence and requests for materials should be addressed to P.M.P. (email: pape@fotonik.dtu.dk)

composition existing in a biofilm makes the treatment of biofilm infections challenging since bacteria in biofilms can employ specific mechanisms to tolerate bactericidal treatments. The origin of biofilm tolerance is mostly caused by low metabolic activity of the bacteria within the biofilm, but it also has a genetic basis^{23,24}. Furthermore, the physical barrier of the biofilm matrix, limits the diffusion of molecules²⁵ into the biofilm, and reduces antimicrobial penetration.

Common sites of biofilm infections in the human body are the oral cavity, e.g. caries is the most frequent disease affecting human health²⁶, burdening billions of individuals with pain, limited masticatory functions and impaired aesthetics. In particular, the deep carious lesions²⁷, as well as its sequelae, the infected root canal associated with biofilm infection, represent targets for improved antimicrobial strategies and represent unsolved demanding challenges within the dental community²⁸. Also within, the urinary system, the lungs of cystic fibrosis patients and chronic wounds biofilm infections are common. Additionally, when medical devices, like catheters, endoscopes, tissue fillers, implants, iatrogenic placed endodontic root filling materials, etc. are inserted into the body, the risk for chronic biofilm infection increases²⁹.

There is urgent need to enable elimination of chronic biofilm infections without utilizing excessive amounts of antibiotics. The present study could assist in developing light assisted combinatory treatments, consisting of irradiation in combination with antibiotics. The scope is to achieve total biofilm eradication and reduce the amount of antibiotics needed for treating infections.

In the present work we aimed to demonstrate the wavelength dependent survival of 24 h (h) grown *P. aeruginosa* biofilms in the range 249 nm to 338 nm with an approximate step of 5 nm. The photon rate was 0.0036 mol/m²; corresponding to a radiant exposure of 1.700–1.260 J/m². We report remarkable eradication (eradication log higher than 8) for the 24 h old biofilms after irradiation in the 292–306 nm range for 0.0495 mol/m² photon rate, corresponding to a radiant exposure 17.500–21.100 J/m². A UVC treatment at that exposure level could have negative implications to the healthy tissue infected by the biofilm; therefore, the wavelengths tested at this higher level of radiant exposure were restricted only to the UVB and UVA region.

To demonstrate the antimicrobial effect of the irradiation method, we compared the irradiation strategy with two types of antibiotics that are well recognized for their usage against *P. aeruginosa* biofilm infections, namely tobramycin³⁰ and colistin³¹ both as monotherapy. The hypothesis was no difference of the eradication efficacy of the three different treatments: UVB or antibiotic monotherapies, on *in vitro* *P. aeruginosa* biofilms either grown for 24 h or 48 h.

Light assisted antibiotic treatments for biofilm infections could be a method to improve the therapy of biofilm infections in the future, since light has been shown to have antibacterial action at several wavelengths⁷: UVC, UVB, UVA, blue, infrared. Here, we demonstrate the light assisted antibiotic principle in specific, by applying irradiation with a UV LED exhibiting central wavelength at 296 nm and by subsequently administrating topically tobramycin, to combat bacteria of *P. aeruginosa* biofilms grown for 24 h (immature) or 48 h (mature). The biofilm eradication of the light assisted tobramycin is compared to the effect achieved by 10-fold more concentrated tobramycin, as well as combinatory antibiotic treatments, consisting of tobramycin and colistin at two concentration levels. Tobramycin and colistin are known to be used in combination due to the increased effectiveness of the combined treatment compared to monotherapy¹⁸. The hypothesis was no difference of the eradication efficacy of the four different treatments: light assisted tobramycin or 10-fold more concentrated tobramycin monotherapy and combinatory antibiotics at two different concentration levels, on *in vitro* *P. aeruginosa* biofilms either grown for 24 h or 48 h.

The proposed method is relevant for combating biofilms and could assist in developing new combinatory therapies consisting of light application and usage of antibiotics to improve treatment of chronic biofilm infections in complex ecosystems e.g. the dental root canal system³², as well as treating postoperative infection adjacent to biomedical implants.

Results

Wavelength dependent survival of biofilms. The survival of the biofilms after each treatment, was calculated according to Eq. 1

$$\log survival = \log \left(\frac{N_{treated}}{N_{control}} \right) = - \log eradication \quad (1)$$

where $N_{treated}$ is the number of colony forming units (CFUs) per micropore filter after a treatment is applied to the biofilm, and $N_{control}$ is the number of CFUs per micropore filter of non-treated samples. The wavelength dependent survival of the *P. aeruginosa* biofilms grown for 24 h is presented in Fig. 1. All treatments were repeated on three different biological replicates.

UVA irradiations were performed with LEDs having central wavelengths from 318 nm to 338 nm, UVB irradiations from 281 nm to 313 nm, covering the whole UVB spectral range, and UVC irradiations from 249 nm to 274 nm. It was observed that the estimated CFUs of the UVA treated samples, independently of wavelength applied, were similar to non-treated samples (control). The log survival was 0.13 ± 0.17 . Independently of wavelength, UVC treated samples exhibited a log eradication 0.36 ± 0.15 (Eq. 1). UVB irradiated samples to the contrary exhibited strong dependence of wavelength and eradication ability and less CFUs were observed, especially for the range 292 to 300 nm. The treatment with the diode having central wavelength at 296 nm exhibited the strongest eradication potential on *P. aeruginosa* 24 h grown biofilms with log eradication 2.39 ± 0.78 .

The eradication ability at a radiant UVB exposure, equivalent to 12 h of summer sunlight in Northern Europe, was remarkable (eradication log higher than 8) for the wavelength range 292–306 nm (Fig. 2). The observed result suggested that a UVB radiant exposure of that level and at this wavelength range could also enact eradication effects on mature biofilms that are known for their increased tolerance to antibacterial treatments.




Figure 1. Wavelength dependent survival of *P. aeruginosa* biofilm grown for 24 h. The photon rate delivered on the biofilms by the UV LEDs was 0.0036 mol/m^2 , corresponding to a radiant exposure 1.260 J/m^2 to 1.700 J/m^2 , respectively, for the wavelengths 338 nm to 249 nm. Three biological replicates were generated for all treatments.




Figure 2. Survival of biofilm after UVB or UVA LED exposure, the level of exposure was equivalent to what can be received by sunlight. The photon rate delivered on the biofilms by the UVB and UVA LEDs was 0.0495 mol/m^2 , corresponding to a radiant exposure 17.500 J/m^2 to 21.100 J/m^2 . The biofilms were *P. aeruginosa* and grown for 24 h. The peculiar observation indicated by the black arrow led us to perform several repetitions of this specific treatment; all repetitions resulted in log eradication higher than 8. The dashed box comprises measurements corresponding to zero counts. The measurements in the dashed box in Fig. 2 correspond to zero counts, i.e. complete eradication of the biofilm.

UVB irradiation treatment versus topically administrated antibiotics. Three treatments were applied on *P. aeruginosa* biofilms grown for 24 h or 48 h, namely UVB irradiation (sunlight equivalent, 20.000 J/m^2), or topical administration of antibiotics; either tobramycin or colistin at one hundred times the minimal inhibitory concentration (MIC). Two-way analysis of variance (ANOVA) revealed that there was a significant difference in eradication of biofilms for the three treatments for 24 h grown biofilms. UVB, compared to colistin or tobramycin, was significantly better at eradicating 24 h immature biofilms with p. values of $P < 0.0001$ and $P < 0.0001$, respectively. No significant difference was observed for the 48 h grown biofilm.

The biofilm eradication achieved by the three different treatments is presented in Fig. 3. The eradication achieved by the UVB irradiation treatment was lower on mature biofilms ($1.11 \pm 0.13 \text{ log eradication}$) than on immature biofilms ($6.31 \pm 1.58 \text{ log eradication}$). However, the UVB treatment was more efficient in eradicating biofilms than the antibiotics. The colistin treatment resulted in negligible eradication, independently of the




Figure 3. Eradication of biofilms after UVB irradiation treatment (sunlight equivalent), or topical administration of antibiotics; colistin or tobramycin at hundred times the MIC. The biofilms were either left to grow for 24 h before treatment or for 48 h. The error bars indicate the standard deviation as acquired by three biological replicates. “MIC” stands for minimal inhibitory concentration.

biofilm growth. The tobramycin treatment enacted a moderate eradication on immature biofilms (1.34 ± 0.08 log eradication), but only negligible eradication on mature biofilms.

Light assisted antibiotics. The CFU/filter values of the different treatments on 24 h and 48 h grown biofilms are presented in Table 1 together with the ones of untreated reference samples. The measurements include UVB, colistin (100MIC), tobramycin (100MIC), tobramycin (1000MIC), tobramycin (100MIC) + colistin (100MIC), tobramycin (1000MIC) + colistin (300MIC), UVB + tobramycin (100MIC). All treatments were repeated on three different biological replicates. For each biological replica, two technical replicas were applied and the average CFU/filter value of the two replicas was taken and shown in Table 1.

The biofilm eradication achieved by the suggested method of light assisted antibiotics on mature samples is presented in Fig. 4. The eradication achieved by combinatory administration of antibiotics, and after administration of highly concentrated monotherapy is also shown in Fig. 4. The one-way ANOVA analysis showed that there was a significant difference (p-value 0.0003) in the eradication achieved by the light-assisted treatment UVB + tobramycin (100MIC) shown in Fig. 4 and the treatment tobramycin (100MIC) shown in Fig. 3 for 48 h grown biofilms.

The light assisted tobramycin was even more effective than the combinatory antibiotics tobramycin and colistin (low-level concentration); and for 48 h biofilms the method of light assisted antibiotics was approximately equally as effective as 10 times higher concentration of tobramycin. Interestingly, the light assisted tobramycin treatment approached the eradication values achieved by topical administration of combinatory antibiotics at high concentrations.

Discussion

In vivo and *in vitro* experiments have previously validated that the tolerance for biofilms are usually considerably higher (approx. 10–1000 times) than the planktonic bacterial cells³³. Therefore, eradication of biofilms by conventional antibiotic administration can be challenging due to potential side effects or accumulated toxicity³⁴. The demand for discovering alternative methods to eradicate biofilms, which may be involved in chronic infections, has been identified for a long time. Moreover, the need to develop treatments that would increase the vulnerability of biofilms to well-recognized therapeutic methods (e.g. antibiotics) has been acknowledged³⁵. The established root canal infection associated with an apical periodontitis (i.e. inflammation surrounding the apical portion of the dental root) provides an area where light assisted antibiotics is applicable, as the prevailing combination of instrumentation and use of medicaments (e.g. sodium hypochlorite) do not completely sterilize the root canal system³⁶. The concept of irrigation with MTAD (antibiotic solution) might be improved in combination with UV irradiation³⁷. In addition, postoperative infections adjacent to biomedical dental implants remain a significant problem, which can lead to early implant failure³⁸. The use of systemic antibiotics does not exert a significant preventive effect against these postoperative infections³⁹. Thus, a final definition is still lacking of which drugs and administration regimens are the most effective antibiotic treatment protocol. The concept presented in this paper represents an option that could be used for treating established implant infections.

Several bacterial species have previously been studied for their sensitivity towards UV irradiation, like *Escherichia coli*⁴⁰, and the optimal germicidal wavelength was found to lie within the UVC range with a maximum around 270 nm. However, the germicidal efficiency was studied for bacteria in the planktonic state. Bacteria in

Treatment	Biofilms											
	1treat		1ref		2treat		2ref		3treat		3ref	
	24 hours	48 hours	24 hours	48 hours	24 hours	48 hours	24 hours	48 hours	24 hours	48 hours	24 hours	48 hours
UVB	1,67E+02	2,59E+08	1,85E+09	4,25E+09	8,31E+04	3,14E+08	2,64E+09	4,47E+09	1,50E+02	4,87E+08	3,65E+09	4,49E+09
colistin(100MIC)	1,16E+09	2,73E+09	2,14E+09	4,63E+09	1,97E+09	3,41E+09	4,29E+09	4,75E+09	1,73E+09	3,18E+09	4,07E+09	4,85E+09
tobramycin(100MIC)	1,08E+08	3,40E+09	2,14E+09	4,63E+09	1,57E+08	3,32E+09	4,29E+09	4,75E+09	2,03E+08	3,69E+09	4,07E+09	4,85E+09
tobramycin(1000MIC)	1,15E+07	6,21E+06	8,33E+09	8,64E+09	6,50E+06	1,53E+07	4,82E+09	1,05E+10	8,00E+06	1,15E+07	6,97E+09	8,18E+09
tobramycin(100MIC) + colistin(100MIC)	3,09E+06	1,58E+09	2,14E+09	4,63E+09	9,31E+06	1,09E+09	4,29E+09	4,75E+09	2,84E+06	1,27E+09	4,07E+09	4,85E+09
tobramycin(1000MIC) + colistin(300MIC)	0,00E+00	3,94E+05	8,33E+09	8,64E+09	0,00E+00	3,05E+05	4,82E+09	1,05E+10	0,00E+00	3,24E+05	6,97E+09	8,18E+09
UVB + tobramycin(100MIC)	0,00E+00	1,35E+07	1,85E+09	4,25E+09	0,00E+00	2,36E+07	2,64E+09	4,47E+09	2,70E+03	1,96E+06	3,65E+09	4,49E+09

Table 1. CFU/filter values of *P. aeruginosa* biofilms after different treatments and the ones of untreated reference samples. *P. aeruginosa* biofilms grown by 24 h and 48 h were investigated. '24 hours' and '48 hours' refer to the biofilm state; '1', '2', '3' refer to the biological replicates; 'treat' refers to the CFU/filter value after irradiations; and 'ref' refers to the CFU/filter value without treatment, as reference sample.




Figure 4. Eradication of biofilms achieved by light assisted tobramycin versus topical administration of 10-fold more concentrated tobramycin or combinatory antibiotics at two concentration levels. The biofilms were grown for 48 h before treatment. The error bars indicate the standard deviation as acquired by three biological replicates. "MIC" stands for minimal inhibitory concentration.

the planktonic state exist as individuals, while biofilms are aggregated bacteria. The peak of absorption of bacterial genetic material is located a few nanometers lower around 260–265 nm⁴¹, and this supported the hypothesis that direct UVC absorption by bacterial genetic material, inhibits normal replication, and results in bacterial eradication^{42–45}.

In the present study it was shown that the eradication efficiency of UV irradiation on 24 h grown *P. aeruginosa* biofilms is wavelength dependent, and that the optimum region is located in the UVB range around 296 nm (292–300 nm). The maximum optical thickness for the 24 h grown *P. aeruginosa* biofilms treated in the present work was $75 \pm 17 \mu\text{m}$ and for the 48 h grown $104 \pm 12 \mu\text{m}$. The maximum physical thickness was respectively $100 \pm 23 \mu\text{m}$ and $138 \pm 16 \mu\text{m}$ for the 24 and 48 h grown biofilms.

In the biofilm state, the smaller penetration achieved by shorter wavelengths is expected to reduce the eradication efficacy of UVC⁶. In the UVA region and longer wavelengths bacterial eradication is dictated only by indirect pathways like generation of reactive oxygen species, and therefore, the eradication efficiency is much lower⁴⁶. UVB is located spectrally between the UVC and UVA regions; and involves elements from both indirect and direct bacterial impairment^{47,48}. Studies on UVB lethality and mutagenesis of bacterial suspensions have shown that lethality occurs at a few nanometers longer wavelengths than mutagenesis⁴⁹. Photons with UVB wavelengths in the 292–307 nm interval are expected to bring enough energy to break bonds like C-H and N-H⁵⁰, essential for the tertiary structure of proteins and DNA⁵¹. In the human skin, free radical generation exhibits high efficiency for wavelengths around 303 nm (UVB range) and 355 nm (UVA range)⁵². Recently, a product with strong

absorbance at 297 nm was reported by Puri *et al.*⁵³ as present in *Methylobacter tundripaludum* supernatants in a quorum sensing dependent manner. The collected product was reported to have no distinguishable growth inhibitory activity against *E. coli* MG 1655 or *Bacillus subtilis* PY79, however, a possible growth inhibitory action of the product was not excluded for other bacterial species.

The route of antibiotic administration in the present study was that antibiotics were added directly to the biofilm. Therefore, the biofilm should be directly accessible to the antibiotic administration. The level of biofilm tolerance towards UV radiation or antibiotics may depend on how the biofilm has been cultured and which model was used. In the present work, it was demonstrated that when tobramycin at a concentration, which only imposed negligible eradication effect on 48 h grown biofilms, was administered after UVB irradiation; it caused much larger eradication efficacy (2.71 ± 0.57 log eradication) and reached the same eradication values as 10-fold more concentrated tobramycin. The eradication effect from UVB alone on 48 h grown biofilms was significantly lower (1.11 ± 0.13 log eradication). This indicates a synergetic effect of light and antibiotics of which the exact mechanism remains to be understood and optimized according to the taxonomic diversity of the biofilm to be eradicated. The improved synergy for 48 h grown biofilms is interesting since the 48 h grown biofilm have fully developed antibiotic tolerance. It seems that the method of light assisted antibiotics is very suited for eradication of bacteria in mature biofilms with a fully developed tolerance.

Conclusion

In conclusion, we have tested the efficiency of UV irradiation treatments to eradicate *P. aeruginosa* biofilms grown for 24 h in the wavelength range 249 nm to 338 nm with an approximate step of 5 nm. It was shown that the log survival of the biofilm was remarkably reduced for the wavelength range 292–306 nm, and the optimum was located at 296 nm. Moreover, we demonstrated that the UVB irradiation was more efficient than topical administration of antibiotics (colistin or tobramycin at 100 MIC) for eradicating biofilms grown for 24 h or 48 h.

A novel method was introduced, light assisted antibiotics, for eradicating mature biofilms and successfully reducing the amount of antibiotics used for disinfection. A specific light assisted antibiotic example was presented; namely, irradiation with a UV LED exhibiting central wavelength at 296 nm combined with topical administration of tobramycin at 100 MIC. This treatment reduced the bacterial load on 48 h grown biofilms by approximately 3 logs, equivalent to the effect as that achieved by administering 10-fold more concentrated tobramycin (1000 MIC). The eradication achieved by the treatment was observed to be more effective than combinatory antibiotic treatment, 100 MIC of colistin plus 100 MIC of tobramycin. The present study can assist in developing new combinatory treatments consisting of light and usage of antibiotics to improve treatments of chronic biofilm infections within chronic wounds or within the infected root canal system treating infections in the jaw.

Methods

Biofilm preparation. The bacterial strain used in the experiments was *P. aeruginosa* PAO1 obtained from the Pseudomonas Genetic Stock Center (strain PAO0001, www.pseudomonas.med.ecu.edu)⁵⁴. The micropore assay methodology used to form the biofilms was based on Bjarnsholt *et al.*⁵⁵, in brief: The Micro-pore assay is based on biofilms growing on a micropore filter on AB minimal medium supplemented with glucose and mixed with 2.0% agar (AGBT) (Substrate Department at the Panum Institute, Denmark). The Cellulose nitrate membrane filters with pore size 0.2 μm and diameter 25 mm purchased from Whatman GmbH (Germany) were placed on top of the ABGT plate. Bacteria from overnight cultures are propagated on the micro-pore filters as spots of 20 μl bacterial suspensions and incubated at 37 °C. For a mature biofilm to develop the filters were transferred to a fresh AB minimal agar plate after 24 h. Treatments were applied to the biofilms after either 24 h (immature biofilm) or 48 h (mature biofilm) incubation in total, at 37 °C⁵⁶. It is observed that the control biofilms have a bacterial density in a level of 10^9 – 10^{10} CFU/filter.

Biofilm thickness measurement. Maximum biofilm thickness was measured by staining filter biofilms with 10 μl (2.5 μM) of universal fluorescent nucleotide stain Syto9 (Invitrogen, USA). Biofilms were imaged as a line-box, measuring 10171 μm (X) × 60.25 μm (Y) × 294 μm (Z) with 5 μm increments in the Z direction on confocal microscope (Zeiss Imager.Z2 microscope with LSM 710 CLSM running Zeiss Zen 2010 v. 6.0. (Zeiss, Germany)). A 488 nm laser was used for excitation and a 505–525 nm filter with a peak at 509 nm for emission. These settings provided a profile image as a cross-section from edge to edge of the filter biofilm. With the use of Imaris 9.0 (Bitplane, Schweiz) thickness of the biofilm was measured. In the format “section view” the profile of the biofilm could be measured as the length from the top point to the base of on the filter membranes surface. The biofilms were measured at the highest point at the edge, approx. 300 μm from edge on each side of the biofilm; additionally, the center of the biofilm was measured as well.

UV Irradiations. The UV LEDs that were used to perform the irradiation treatments were purchased from Sensor Electronic Technology, Inc (SETi, Columbia, SC, USA). The spectral irradiance of the diodes used to determine the optimal biofilm eradication wavelength, is depicted in Fig. 5. The spectral irradiance was measured by an External Optical probe (EOP-146, Instrument Systems GmbH, Munich, Germany) and a monochromator. The spectrometer used was a SPECTRO 320 (D) Release 5 (Instrument Systems GmbH). The exact protocol for measuring the spectral irradiance can be found in Barnkob *et al.*⁵⁷. The irradiance delivered on the biofilms was measured with a portable radiometer (NIST Certified UV Radiometer) at a distance (1.5 ± 0.1 cm). The distance between the biofilms and the UV LEDs was 1.5 ± 0.2 cm for all exposures; the error originates from the agar height, on which the filter carrying the biofilm was placed. The biofilms were kept in a UV free environment, when not treated. The UV treatment was conducted at a temperature of 20 °C for all the samples.




Figure 5. Spectral irradiance of UV LEDs used for determination of the optimal biofilm eradication wavelength. The UVC diodes are indicated with cyan color and dash line. The UVB diodes are indicated by black line, and black short dash for the optimal diode, central wavelength at 296 nm. UVA diodes are indicated by orange dash dot line.

Antibiotic treatments. The antibiotics used in this study were tobramycin (Eurocept International, Netherlands) and colistin sulfate salt (Sigma-Aldrich, USA). The MIC concentration for colistin was determined as 0.8 µg/mL and for tobramycin 1 µg/mL. The antibiotic treatments delivered were: 100 µg/mL tobramycin (100 MIC); 80 µg/mL colistin sulfate salt (100 MIC); tobramycin and colistin high (tobramycin + colistin high): 1000 µg/mL tobramycin (1000 MIC) and 250 µg/mL colistin sulfate salt (~300 MIC); tobramycin and colistin low (tobramycin + colistin low): 100 µg/mL tobramycin and 80 µg/mL colistin sulfate salt; 1000 µg/mL tobramycin (1000 MIC). For the light assisted antibiotic treatment; 100 µg/mL tobramycin were delivered after UVB was applied (sunlight equivalent, 20.000 J/m²). The antibiotics were added into the ABTG agar plates and biofilms were treated by moving the biofilm growing on nitrocellulose filters to the antibiotic containing media plates.

CFU determination. The method for quantitative bacteriology is described in Argyraki *et al.*⁶; and distinct samples were used for the CFU determination. Following treatment the filter biofilm was transferred with sterile forceps to 5 mL saline (0.9% NaCl) and detached through sonication in an Branson B2510-DTH ultrasonic cleaner (5 min degas followed by 5 min sonication). Serial dilutions in the cases of UVB irradiation treatment versus topically administrated antibiotics and light assisted antibiotics were performed from 10⁰ (no dilution) to 10⁻⁷ and the spotted volume was 10 µL performed in triplicate; resulting in a detection limit of 100 bacteria per ml.

Statistics. All treatments were performed on three different biological replicates (n = 3), based on two or three technical replicates, as a standard for testing reproducibility. The statistical dispersion was measured as standard deviation, reported in errors, and is of biological origin if not stated otherwise in the text. One-way ANOVA or two-way ANOVA followed by Bonferoni corrected multiple comparison were performed in GraphPad Prism 7.01.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- <http://www.who.int/mediacentre/factsheets/fs194/en/> (World health organization).
- Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents*. **35**(4), 322–332 (2010).
- Neu, H. C. The crisis in antibiotic resistance. *Science* **257**(5073), 1064 (1992).
- Yin, R. *et al.* Light based anti-infectives: ultraviolet C irradiation, photodynamic therapy, blue light, and beyond. *Curr. Opin. Pharmacol.* **13**(5), 731–762 (2013).
- Bak, J., Jørgensen, T. M., Helfmann, J., Gravemann, U. & Vorontsova, I. Potential *in vivo* UVC disinfection of catheter lumens: estimation of the doses received by the blood flow outside the catheter tip hole. *Photochem. Photobiol.* **87**(2), 350–356 (2011).
- Argyraki, A., Markvart, M., Bjørndal, L., Bjarnsholt, T. & Petersen, P. M. Inactivation of *Pseudomonas aeruginosa* biofilm after ultraviolet light-emitting diode treatment: a comparative study between ultraviolet C and ultraviolet B. *J. Biomed. Opt.* **22**(6), 065004–065004 (2017).
- Tianhong, D. *et al.* Blue light rescues mice from potentially fatal *Pseudomonas aeruginosa* burn infection: efficacy, safety, and mechanism of action. *Antimicrob. Agents Chemother.* **57**(3), 1238–1245 (2013).
- Taniyasu, Y., Kasu, M. & Makimoto, T. An aluminium nitride light-emitting diode with a wavelength of 210 nanometres. *Nature* **441**(7091), 325–328 (2006).
- Gaska, R., Zhang, J. & Shur, M. U. S. Patent 7,491,626 (2009).

10. Wang, H. M. *et al.* AlN/AlGa_N superlattices as dislocation filter for low-threading-dislocation thick AlGa_N layers on sapphire. *Appl. Phys. Lett.* **81**, 604–606 (2002).
11. Hirayama, H., Maeda, N., Fujikawa, S., Toyoda, S. & Kamata, N. Recent progress and future prospects of AlGa_N-based high-efficiency deep-ultraviolet light-emitting diodes. *Jpn. J. Appl. Phys.* **53**(10), 100209 (2014).
12. Hirayama, H., Yatabe, T., Noguchi, N., Ohashi, T. & Kamata, N. 231–261 nm AlGa_N deep-ultraviolet light-emitting diodes fabricated on AlN multilayer buffers grown by ammonia pulse-flow method on sapphire. *Appl. Phys. Lett.* **91**(7), 071901 (2007).
13. Zhao, S. Aluminum nitride nanowire light emitting diodes: Breaking the fundamental bottleneck of deep ultraviolet light sources. *Sci. Rep.* **5**, 8332 (2015).
14. Gao, N. *et al.* Surface-plasmon-enhanced deep-UV light emitting diodes based on AlGa_N multi-quantum wells. *Sci. Rep.* **2**, 816 (2012).
15. Inazu, T. *et al.* Improvement of light extraction efficiency for AlGa_N-based deep ultraviolet light-emitting diodes. *Jpn. J. Appl. Phys.* **50**(12R), 122101 (2011).
16. Shatalov, M. *et al.* AlGa_N deep-ultraviolet light-emitting diodes with external quantum efficiency above 10%. *Appl. Phys. Express* **5**(8), 0821011–3 (2012).
17. Wu, H., Moser, C., Wang, H. Z., Hoiby, N. & Song, Z. J. Strategies for combating bacterial biofilm infections. *Int. J. Oral Sci.* **7**(1), 1–7 (2015).
18. Herrmann, G. *et al.* Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm *Pseudomonas aeruginosa*. *J. Infect. Dis.* **202**(10), 1585–1592 (2010).
19. Christensen, L. D. *et al.* Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against *Pseudomonas aeruginosa* in an intraperitoneal foreign-body infection mouse model. *J. Antimicrob. Chemother.* **67**(5), 1198–1206 (2012).
20. Gunderson, B. W. *et al.* Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant *Pseudomonas aeruginosa* in an *in vitro* pharmacodynamic model. *J. Antimicrob. Chemother.* **47**(3), 905–909 (2003).
21. Gordon, N. C., Png, K. & Wareham, D. W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of *Acinetobacter baumannii*. *J. Antimicrob. Chemother.* **54**(12), 5316–5322 (2010).
22. Stewart, P. S. & Costerton, J. W. Antibiotic resistance of bacteria in biofilms. *Lancet* **358**(9276), 135–138 (2001).
23. Mah, T. F. *et al.* A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature* **426**(6964), 306–310 (2003).
24. Drenkard, E. & Ausubel, F. M. *Pseudomonas* biofilm formation and antibiotic resistance are linked to phenotypic variation. *Nature* **416**(6882), 740–743 (2002).
25. Kim, Y. W. *et al.* Effect of electrical energy on the efficacy of biofilm treatment using the bioelectric effect. *NPJ Biofilms Microbiomes* **1**, 15016 (2015).
26. Kassebaum, N. J. Global burden of untreated caries: a systematic review and metaregression. *J. Dent. Res.* **94**(5), 650–658 (2015).
27. Bjørndal, L. *et al.* Randomized Clinical Trials on Deep Carious Lesions: 5-Year Follow-up. *J. Dent. Res.* **96**(7), 747–753 (2017).
28. Demant, S., Markvart, M. & Bjørndal, L. Quality-Shaping Factors and Endodontic Treatment amongst General Dental Practitioners with a Focus on Denmark. *Int. J. Dent.* **2012**(526137), 1–7 (2012).
29. Bjørndal, L. *et al.* Maxillary Sinus Impaction of a Core Carrier Causing Sustained Apical Periodontitis, Sinusitis, and Nasal Stenosis: A 3-year Follow-up. *J. Endod.* **42**, 1851–1858 (2016).
30. Ramsey, B. W. *et al.* Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. *N. Engl. J. Med.* **340**, 23–30 (1999).
31. Beringer, P. The clinical use of colistin in patients with cystic fibrosis. *Curr. Opin. Pulm. Med.* **7**(6), 434–440 (2001).
32. Markvart, M. *et al.* Micro-CT analyses of apical enlargement and molar root canal complexity. *Int. Endod. J.* **45**(3), 273–281 (2012).
33. Hengzhuang, W., Wu, H., Ciofu, O., Song, Z. & Hoiby, N. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid *Pseudomonas aeruginosa* biofilms. *Antimicrob. Agents Chemother.* **55**(9), 4469–4474 (2011).
34. Patrick, B. N., Rivey, M. P. & Allington, D. R. Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. *Ann. Pharmacother.* **40**(11), 2037–2042 (2006).
35. Taraszewicz, A., Fila, G., Grinholc, M. & Nakonieczna, J. Innovative strategies to overcome biofilm resistance. *BioMed Res. Int.* **2013**(150653), 1–13 (2013).
36. Markvart, M., Dahlén, G., Reit, C. E. & Bjørndal, L. The antimicrobial effect of apical box versus apical cone preparation using iodine potassium iodide as root canal dressing: a pilot study. *Acta Odontol. Scand.* **71**, 786–791 (2013).
37. Dubey, S., Saha, S. G., Rajkumar, B. & Dhole, T. K. Comparative antimicrobial efficacy of selected root canal irrigants on commonly isolated microorganisms in endodontic infection. *Eur. J. Dent.* **11**(1), 12–16 (2017).
38. Camps-Font, O., Figueiredo, R., Valmaseda-Castellon, E. & Gay-Escoda, C. Postoperative infections after dental implant placement: prevalence, clinical features, and treatment. *Implant Dent.* **24**(6), 713–719 (2015).
39. Ata-Ali, J., Ata-Ali, F. & Ata-Ali, F. Do antibiotics decrease implant failure and postoperative infections? A systematic review and meta-analysis. *Int. J. Oral Maxillofac. Surg.* **43**(1), 68–74 (2014).
40. Wang, T., MacGregor, S. J., Anderson, J. G. & Woolsey, G. A. Pulsed ultra-violet inactivation spectrum of *Escherichia coli*. *Water Res.* **39**(13), 2921–2925 (2005).
41. Harm, W. *Biological effects of Ultraviolet Radiation* (Cambridge University Press, 1980).
42. Bonura, T. & Smith, K. C. Enzymatic production of deoxyribonucleic acid double-strand breaks after ultraviolet irradiation of *Escherichia coli* K-12. *J. Bacteriol.* **121**(2), 511–517 (1975).
43. Bonura, T. & Smith, K. C. Quantitative evidence for enzymatically-induced dna double-strand breaks as lethal lesions in uv irradiated pol + and polal strains of *e. coli* K-12. *Photochem. Photobiol.* **22**(6), 243–248 (1975).
44. Kuluncsics, Z., Perdiz, D., Brulay, E., Muel, B. & Sage, E. Wavelength dependence of ultraviolet-induced DNA damage distribution: involvement of direct or indirect mechanisms and possible artefacts. *J. Photochem. Photobiol. B.* **49**(1), 71–80 (1999).
45. Koller, L. R. *Ultraviolet Radiation* (John Wiley & Sons, 1952).
46. Amiri, N., Finkbeiner, M., Hamilton, S. & Kibenge, P. The role of reactive oxygen species in UVA-mediated killing of *Escherichia coli*. *J. Exp. Microbiol. Immunol.* **11**, 42–46 (2007).
47. Santos, A. L. *et al.* Wavelength dependence of biological damage induced by UV radiation on bacteria. *Arch. Microbiol.* **195**(1), 63–74 (2013).
48. Qiu, X., Sundin, G. W., Wu, L., Zhou, J. & Tiedje, J. M. Comparative analysis of differentially expressed genes in *Shewanella oneidensis* MR-1 following exposure to UVC, UVB, and UVA radiation. *J. Bacteriol.* **187**(10), 3556–3564 (2005).
49. Peak, M. J., Peak, J. G., Moehring, M. P. & Webs, R. B. Ultraviolet action spectra for DNA dimer induction, lethality, and mutagenesis in *Escherichia coli* with emphasis on the UVB region. *Photochem. Photobiol.* **40**(5), 613–620 (1984).
50. Vermeulen, N., Keeler, W. J., Nandakumar, K. & Leung, K. T. The bactericidal effect of ultraviolet and visible light on *Escherichia coli*. *Biotechnol. Bioeng.* **99**(3), 550–556 (2008).
51. Lodish, H. *et al.* *Molecular cell biology* (Scientific American Books, Inc., 1995).
52. Zastrow, L. *et al.* The missing link—light-induced (280–1600 nm) free radical formation in human skin. *Skin Pharmacol. Physiol.* **22**(1), 31–44 (2009).
53. Puri, A. W. *et al.* Quorum sensing in a methane-oxidizing bacterium. *J. Bacteriol.* **199**(5), 00773–16 (2017).
54. Stover, C. K. *et al.* Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* **406**(6799), 959–964 (2000).

55. Bjarnsholt, T. *et al.* Antibiofilm properties of acetic acid. *Adv. Wound Care* **4**(7), 363–372 (2015).
56. Bjarnsholt, T. *et al.* Applying insights from biofilm biology to drug development - can a new approach be developed? *Nat. Rev. Drug Discov.* **12**(10), 791–808 (2013).
57. Barnkob, L. L., Argyraki, A., Petersen, P. M. & Jakobsen, J. Investigation of the effect of UV-LED exposure conditions on the production of vitamin D in pig skin. *Food Chem.* **212**, 386–391 (2016).

Acknowledgements

The authors thank Anne Nielsen for her help in the laboratory, Sabrina Gericke for the blind counting of the CFUs and P.S. Ramanujam for the helpful discussions. For financial support we would like to thank Region Zealand in Denmark (“the photonics green lab DOLL”, grant number: 2075008) and T.B. would like to thank the Lundbeck Foundation for financial supported through grant R105-A9791.

Author Contributions

All authors discussed the design of the study, the results, and contributed to the preparation of the manuscript. A.A. analyzed the data, performed irradiation treatments and wrote the majority of the manuscript. P.M.P. conceptualized the irradiation treatments. M.M. grew the biofilms, analyzed data and performed the serial dilutions; for the wavelength dependence related data. C.S. grew the biofilms and performed the serial dilutions for the comparisons to antibiotics and light assisted treatments; performed the antibiotic treatments; and analyzed the raw data. Y.O. analyzed the raw data and contributed with a discussion about the synergy between light and antibiotics. K.N.K. performed the biofilm thickness measurements. L.B. and M.M. designed the dental aspects of the study. T.B. designed the microbiological aspect of the study, analyzed microbiological data, as well as assisted in writing the microbiology part of the manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018